Catenion Arno Heuermann 2

Arno Heuermann

Arno Heuermann is a founding Partner of Catenion who lives in Berlin, Germany. Arno has ten years of experience as CEO and COO. He has managed companies in Germany, France and Luxemburg.

While working on his degrees, Arno founded a technical engineering office in 1994. He continued to follow the entrepreneurial path in 1998 by founding Biopsytec GmbH, a DNA diagnostics company focused on agriculture, heading the company for more than five years as Managing Director.

In 1999, he co–founded Epigenomics AG, a public biotech company focused on DNA methylation, later remaining as an advisor and member of the firm’s Supervisory Board.

In August 2000, Arno orchestrated the founding and financing of Biopsytec Holding AG, thus merging Genious SA and the QTL AG and Biopsytec GmbH. He managed Biopsytec Holding AG for the next three years before helping launch Catenion in 2003. Since that time, he has been Catenion’s chief operating officer.

Arno holds a diploma degree in process engineering from the Technical University of Applied Sciences in Berlin. In addition, Arno attended the Berlin business school for Industrial Engineering and Management.

He is experienced in the diverse practices of patent management and has made numerous successful inventions.

Arno Heuermann is married and has two children. He is a lover of classical music, country life and horseback riding.

Catenion Matthias Krings

Dr. Matthias Krings

Matthias Krings is a founding Partner of Catenion.

He has worked for international pharma, biotech and medtech organizations on a variety of topics. Matthias works with clients on developing corporate and R&D strategies, identifying new areas of opportunity, tailoring asset and company searches for BD&L and M&A, maximizing the value of existing assets through therapeutic expansion, and prioritizing R&D portfolios. Matthias is also resposible for the creation and delivery of bespoke client education programs in the Catenion Academy.

Before co-founding Catenion in 2003, Matthias was a consultant at Mercer Management Consulting (now Oliver Wyman) and later joined a strategy consulting boutique, Theron.

Matthias holds a diploma and a doctorate degree in Biology from the Ludwig-Maximilians University in Munich. His PhD work was supported by a scholarship from the Boehringer Ingelheim Fonds, Foundation for Basic Research in Medicine. Matthias made significant scientific contributions to the field of human evolution (Krings et al., Cell 1997: Neandertal DNA Sequences and the Origin of Modern Humans).

Matthias lives in Munich & Berlin. He enjoys cooking, gardening, watersports and traveling.

Matthias co-authored Catenion’s Commentaries “Elements of Winning Strategies in R&D” and “Recombinant Portfolio Management – Recognizing and Enabling Innovation”. They are part of Catenion’s “Shaping Pharmaceutical Strategy” series that focuses on high-profile issues for the industry.

Catenion Christian Elze

Christian Elze

Christian Elze is a founding partner of Catenion and has been developing the company’s business in Japan since 2008. He holds a BSc from the London School of Economics and an MBA from Columbia University.

Christian is working with companies, universities and governments in the field of biomedical innovation. In his work, Christian is focusing on how emerging technologies and translational research are re-shaping the respective roles of funding agencies, investors, biopharma companies and academia in the research and development of new drugs.

Besides his consulting work, Christian frequently speaks about Emerging Technologies, Healthcare Reform, Pricing & Reimbursement,  Biomedical Innovation, as well as Translational Research at industry conferences and universities in Japan, the US and Europe.

Christian is a fluent speaker of English, French, German, Italian, Portuguese, Russian and Spanish and lives with his family in London.

Catenion Markus Thunecke compressed


マチアスは、「企業ポートフォリオ戦略のリスク・プロファイル」や、「R&Dにおける成功戦略の要素」、「組み換えイノベーション管理(RIM) – 大規模R&D組織でイノベーティブなブレークスルーを生み出す方法」、「組み換えポートフォリオ管理 – イノベーションを認識し育てる」など、いくつかのカテニオン・コメンタリーを書いています。 また共著には、「ゼロベースからのR&D]や、「日本医薬品企業上位20社の課題」などがあります。 これらはみな、医薬品業界にとって重要な問題にフォーカスしたカテニオンの「医薬品戦略の策定」シリーズに入っています。

マーカス・ツーネッケ は、カテニオンの創設メンバーでシニアパートナーです。ドイツ・ベルリンに住んでいます。 マーカスは、 1997年にマーサー・マネジメント・コンサルティングでコンサルタントのキャリアをスタートしました。その後、戦略コンサルティング会社セロンで働き、2003年にカテニオン創設に参加しました。

マーカスはこれまで、世界中の数多くの医薬品及び医療製品業界のクライアント に、競争に打ち勝ち優位性を築くための助言をしてきました。 戦略以外にも、 最先端の分析ツールの開発や、開発したツールと組織開発能力を組み合わせることも専門です。 マーカスは、カテニオン独自のポートフォリオ管理やリスク・アセスメントのツールを数多く開発しました。 最近の例では、マーカスは、クライアントのR&D戦略の開発と調整、ディスカバリーと開発ポートフォリオの見直し、イノベーションを育む組織モデルの構築などに携わりました。


彼はハイデルベルク大学で、アルツハイマー症研究に用いる遺伝子組み換え動物モデルを作り、バイオケミストリーの博士号を取得しました。 また、シェーリングで3年間 中枢神経分野の研究をした経験もあります。